For patients with chronic myeloid leukemia in chronic phase (CMLCP), treatment with a BCR-
ABL1 tyrosine kinase inhibitor (TKI), such as imatinib or nilotinib, can result in high response …

We explored the impact of early molecular response (EMR; BCR-ABL≤ 10% on the
international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly …

Abstract Abstract 606 FN2 Background: Recent studies have demonstrated that about 40%
of very highly selected CML-CP pts treated with imatinib achieve durable CMR and may be …

Abstract Introduction The 12-and 24-mo results of the Evaluating Nilotinib Efficacy and
Safety in clinical Trials–complete molecular response (ENESTcmr) trial showed that pts with …

Abstract Abstract 2201 Poster Board II-178 Introduction: Nilotinib, a potent and highly
selective BCR-ABL tyrosine kinase inhibitor (TKI), is approved for the treatment of patients …

Background: ENESTop, an ongoing, single-arm, phase 2 study (ClinicalTrials. gov,
NCT01698905), is the first trial specifically evaluating treatment-free remission (TFR; ie …

7001 Background: In prior clinical trials,≈ 40-60% of pts with CML-CP and sustained deep
molecular response (MR) maintained TFR after stopping long-term imatinib (median …

Abstract Abstract 3431 Background: In the ENESTnd (Evaluating Nilotinib Efficacy and
Safety in Clinical Trials–Newly Diagnosed Pts) trial, nilotinib demonstrated superior efficacy …

Abstract Treatment with a tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is currently the
standard of care for patients with chronic myeloid leukemia (CML) in chronic phase (CML …

Patients in complete cytogenetic response (CCyR) with detectable BCR-ABL1 after≥ 2
years on imatinib were randomized to nilotinib (400 mg twice daily, n= 104) or continued …